Eli Boritz
Overview
Explore the profile of Eli Boritz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1625
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moysi E, Sharma A, ODell S, Georgakis S, Del Rio Estrada P, Torres-Ruiz F, et al.
bioRxiv
. 2024 Aug;
PMID: 39131331
A subset of people living with HIV (PLWH) can produce broadly neutralizing antibodies (bNAbs) against HIV, but the lymph node (LN) dynamics that promote the generation of these antibodies are...
2.
Huang Y, Dhummakupt A, Khetan P, Nilles T, Zhou W, Mudvari P, et al.
Front Immunol
. 2023 Apr;
14:1007626.
PMID: 37033916
HIV-1 infection in memory CD4+ T cells forms a latent reservoir that is a barrier to cure. Identification of immune biomarkers that correlate with HIV-1 reservoir size may aid with...
3.
Suthar M, Arunachalam P, Hu M, Reis N, Trisal M, Raeber O, et al.
Med
. 2022 May;
3(1):25-27.
PMID: 35590141
Antibody responses to the Pfizer-BioNTech mRNA vaccine waned substantially 6 months after the second vaccination.
4.
Corbett K, Gagne M, Wagner D, O Connell S, Narpala S, Flebbe D, et al.
Science
. 2021 Oct;
374(6573):1343-1353.
PMID: 34672695
Neutralizing antibody responses gradually wane against several variants of concern (VOCs) after vaccination with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine messenger RNA-1273 (mRNA-1273). We evaluated the immune...
5.
Corbett K, Gagne M, Wagner D, O Connell S, Narpala S, Flebbe D, et al.
bioRxiv
. 2021 Aug;
PMID: 34426813
One-sentence Summary: mRNA-1273 boosted nonhuman primates have increased immune responses and are protected against SARS-CoV-2 beta infection.
6.
Corbett K, Werner A, O Connell S, Gagne M, Lai L, Moliva J, et al.
Nat Immunol
. 2021 Aug;
22(10):1306-1315.
PMID: 34417590
B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates received...
7.
Edara V, Pinsky B, Suthar M, Lai L, Davis-Gardner M, Floyd K, et al.
N Engl J Med
. 2021 Jul;
385(7):664-666.
PMID: 34233096
No abstract available.
8.
Edara V, Lai L, Sahoo M, Floyd K, Sibai M, Solis D, et al.
bioRxiv
. 2021 May;
PMID: 34013272
SARS-CoV-2 has caused a devastating global pandemic. The recent emergence of SARS-CoV-2 variants that are less sensitive to neutralization by convalescent sera or vaccine-induced neutralizing antibody responses has raised concerns....
9.
Anderson E, Simonetti F, Gorelick R, Hill S, Gouzoulis M, Bell J, et al.
Viruses
. 2020 Jan;
12(2).
PMID: 31991737
Combination antiretroviral therapy (cART) controls but does not eradicate HIV infection; HIV persistence is the principal obstacle to curing infections. The proportion of defective proviruses increases during cART, but the...
10.
Lee E, von Stockenstrom S, Morcilla V, Odevall L, Hiener B, Shao W, et al.
J Virol
. 2019 Nov;
94(3).
PMID: 31723024
Understanding the impact of antiretroviral therapy (ART) duration on HIV-infected cells is critical for developing successful curative strategies. To address this issue, we conducted a cross-sectional/inter-participant genetic characterization of HIV-1...